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Available online 29 January 2016Purpose: A UCB–IBM collaboration explored the application ofmachine learning to large claims databases to con-
struct an algorithm for antiepileptic drug (AED) choice for individual patients.
Methods: Claims data were collected between January 2006 and September 2011 for patients with epilepsy
N16 years of age. A subset of patient claimswith a valid index date of AED treatment change (new, add, or switch)
were used to train the AED prediction model by retrospectively evaluating an index date treatment for subse-
quent treatment change. Based on the trainedmodel, a model-predicted AED regimenwith the lowest likelihood
of treatment changewas assigned to each patient in the group of test claims, and outcomeswere evaluated to test
model validity.
Results: The model had 72% area under receiver operator characteristic curve, indicating good predictive power.
Patients who were given the model-predicted AED regimen had signiﬁcantly longer survival rates (time until a
treatment change event) and lower expected health resource utilization on average than those who received
another treatment. The actual prescribed AED regimen at the index date matched themodel-predicted AED reg-
imen in only 13% of cases; there were large discrepancies in the frequency of use of certain AEDs/combinations
between model-predicted AED regimens and those actually prescribed.
Conclusions: Chances of treatment success were improved if patients received the model-predicted treatment.
Using the model's prediction system may enable personalized, evidence-based epilepsy care, accelerating the
match between patients and their ideal therapy, thereby delivering signiﬁcantly better health outcomes for
patients and providing health-care savings by applying resourcesmore efﬁciently. Our goal will be to strengthen
the predictive power of the model by integrating diverse data sets and potentially moving to prospective
data collection.
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The clinician's ability to identify antiepileptic drug (AED) regimens
that provide each patientwith epilepsywith the best possible outcomes
is a signiﬁcant challenge. Clinical trials rarely provide the speciﬁcity
for individual patient-centric decisions. Even existing epilepsy treat-
ment guidelines provide recommendations on key aspects of care
such as the treatment of new-onset epilepsy [1], treatment-resistant ep-
ilepsy [2], and epilepsy in patients with HIV/AIDS [3], but do not caterunder the curve; CDS, clinical
Diseases, Ninth Revision; ROC,
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r Inc. All rights reserved.speciﬁcally to patients who vary, for example, by age, etiology, and so-
cioeconomic status. Clinicians, therefore, often rely on trial and error.
While seizures in approximately 60% of patients respond to their
ﬁrst AED, another 15% spend 2–5 years ﬁnding an effective AED regi-
men; seizures in the remaining 25–30% are treatment-resistant [4,5].
This indicates a knowledge gap and signiﬁcant unmet medical need re-
garding optimal AED choice for balancing symptom control and tolera-
bility for individuals [6]. Indeed, the initial promise of personalized
medicine was alluring in the management of epilepsy, but it has been
slow to deliver [7,8].
With the increasing amount of clinical data and available AEDs,
application of computer learning and data analysis may help physicians
easily access the most relevant information to make treatment deci-
sions. This approach takes mass quantities of structured and unstruc-
tured data from various sources and asks the computer to learn and
return a set of structured answers based only on the most relevant
data [9]. A clinical decision support (CDS) system for pediatric epilepsy
was developed using a computer system to integrate expert opinion
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[10,11]. A collaboration between UCB and IBM has been made to devel-
op a predictive model offering personalized care for people with epilep-
sy that uses “cognitive computing” to analyze data involving thousands
of longitudinal records, similar to a collaboration between IBM and
Memorial Sloan Kettering Cancer Center developing a system to diag-
nose and treat an individual's cancer [9]. For epilepsy, this modeling ap-
proach leverages the increasing aggregation and collation of claims data
to predict the chances of treatment success, deﬁned by avoidance of
hospitalization or treatment change, based on the similarity of the indi-
vidual patient's characteristics to a larger patient population. Here, we
present our initial ﬁndings in epilepsy.
2. Methods
2.1. Data source and patients
Medical, pharmacy, and hospital claims data were collected from
all major regions of the United States between January 1, 2006 and
September 31, 2011 from the IMS Health Surveillance Data Incorpo-
rated (SDI) medical claims database. This database was chosen because
it broadly reﬂects the underlying population of patients with epilepsy
including census-like geographic coverage, has full representation of
third-party and government payers, and does not require continuous
eligibility in a health plan, ensuring that varying socioeconomic status
and patient movement across plans/payers each year does not impede
the ability to track these patients over time. The SDI database provides
de-identiﬁed patient data in compliancewithHealth Insurance Portabil-
ity and Accountability Act regulations, thus making the study exempt
from institutional review board review.
The SDI aggregates patient information from multiple provider
sources, but might not capture all claims for an individual patient if pro-
viders that do not submit data to SDI were used. To control for this, we
employed eligibility requirements for continuous reporting from the
sources. Speciﬁcally, we required at least 80% continuousmonthly eligi-
bility (in 1-year windows) in any of the SDI pharmacy, physician, or
hospital databases, and quarterly pharmacy eligibility for each patient.
The analysis was performed on the longest eligible data period of the
patient, requiring a minimum period of 2 years.
To capture data frompatientswith epilepsy rather than frompatients
receiving AEDs for other indications, we deﬁned an analysis set of pa-
tients N16 years of age in January 2006, with at least one International
Classiﬁcation of Diseases, Ninth Revision (ICD-9) epilepsy diagnosis code
(345.xx) or two seizure diagnosis codes (780.3x) at any time, as well
as at least one claim for an AED from a pharmacy with 80% stability
(existence of monthly pharmacy claims data) over the whole data
period. The ﬁnal inclusion criterion was that an index date (deﬁned
below) was identiﬁable for the patient.
2.2. Choice of index date
An index date was deﬁned as the ﬁrst date on which a treatment
change occurred, where: (1) the new AED regimen switched one or
more AEDs in the previous regimen or added anAED to the existing reg-
imen (excluding the case of restarting a past treatment, and including
the case of moving from no treatment to AED treatment); (2) the
patient had an eligible period of ≥12 months before and after this
date; (3) the patient had ≥3 months of pharmacy eligibility prior to
this date; and (4) the treatment was unchanged during the 30-day
period after the index date (to eliminate rescue medication in favor of
chronic treatment).
The AED regimen following the treatment change event at the
index date was deﬁned as the index date AED regimen. The 12-month
period before the index date was used to extract patient features,
while the 12-month period after the index date was used to determine
the outcome.2.3. Choice of outcome
Because the primary symptomof epilepsy—seizures—is not captured
in claims data, we used treatment change events as a proxy measure of
seizure control and patient status. Intuitively, the need for treatment
change indicates that the patient's current treatment regimen was
suboptimal in terms of efﬁcacy and/or tolerability. In order to be a
valid index date, the treatment had to remain unchanged for at least
30 days post-index date. Therefore, an unsuccessful AED regimen was
deﬁned as any change other than a dose change (i.e., increase/decrease)
or a complete withdrawal of any AED treatment in the subsequent
1–12 months after the change. Furthermore, longer-term stable treat-
ment or a complete withdrawal from an AED therapy was assumed to
indicate successful treatment.
2.4. Data analysis
The objective of the UCB–IBM collaboration was to retrospectively
estimate the effectiveness of different treatment approaches using
large observational data sets and use this information to predict suc-
cessful treatments for individual patients. We used machine-learning
methods to create a predictive algorithm estimating the success prob-
ability for a given patient and a speciﬁc treatment regimen. This algo-
rithm was then used to predict the treatment regimenwith the highest
success probability for each patient (model-predicted AED regimen).
The effects of using the algorithm's predictions were assessed in terms
of treatment change rates and utilization of health-care services using
an independent patient set.
Disjoint sets of 40,000 patients for training and 10,000 patients
for testing were randomly selected from the patients meeting all
study inclusion criteria. To increase the reliability of the results, we ex-
cluded patientswhose index date treatment regimenwas relatively rare
(i.e., occurred b50 times in the training population).
2.4.1. Building and testing the model
Weused the training set to train a predictivemodel which, given the
patient data 12-month pre-index date and the index date AED regimen,
predicts the probability of success. The predictive model was based on
features extracted from the data, but not costs or health-care utilization
features. From each patient's record, roughly 5000 features were ex-
tracted, which include patient features (related to the patient and re-
corded prior to the index date, e.g., demographics, medication history,
comorbidities, ICD-9 codes), treatment features (related to the index
date AED regimen—the one to be evaluated—e.g., the number and
type of distinct drugs at index date), and patient-treatment features
(interactions between patient and treatment). Some features were
based on expert knowledge or literature (e.g., classiﬁcation of AED as
ﬁrst or second generation, AED activity in particular seizure types,
mechanism of action [12–14]). To reduce the number of features and
avoid over-ﬁtting the training data, we used a standard feature selection
process. First, we removed constant features (mode frequency N 0.99)
and features with small standard deviations. Second, we removed fea-
tures whose correlation to the outcome was not signiﬁcant (p N 0.05).
Finally, we removed features that were highly correlated to another
feature (R N 0.6), where the feature removed was the one with lower
correlation to the outcome. The selected features were based on the
training set only, and when testing, only these selected features were
calculated and used. We used the random forest algorithm [15], a
state-of-the-art prediction model that outputs the majority vote of a
multitude of decision trees because this algorithm outperformed other
prediction algorithms (results not shown).
The performance of the model's predictions was estimated using re-
ceiver operator characteristic (ROC) analysis on the test set. This accura-
cy was compared with the accuracy of a baseline model, which was
deﬁned as a logistic regression on the number of treatment changes
the patient had experienced in the 12 months prior to the index date.
Table 1
Demographics of training set population at the index date. Claims in the 6 months prior
to the index date were 50% commercial/third party, 28% Medicare, 15% Medicaid, and
7% other/cash.
Characteristic n (%)
No. of patients included (%) 34,990 (87)
No. of treatment changes (%) 14,874 (43)
Age (years)
Mean (SD) 52 (16)
17–24 1653 (5)
25–64 25,031 (72)
≥65 8306 (24)
Sex, female 22,370 (64)
Region
Northeast 4497 (13)
Midwest 6328 (18)
South 9606 (27)
West 6835 (20)
Unknowna 7724 (22)
Specialty of the physician prescribing the index date AED treatment
Neurologist 10,365 (30)
Internal medicine 4891 (14)
Family practice 4470 (13)
Psychiatry 1994 (6)
Other 7721 (22)
Unknown 5549 (16)
No. of AEDs at index date
Mean (SD) 1.4 (0.5)
1 AED 23,024 (66)
2 AEDs 11,609 (33)
3 AEDs 357 (1)
Most common AED treatments at index dateb
Levetiracetam 8603 (25)
Gabapentin 7183 (21)
Phenytoin 6539 (19)
Clonazepam 4916 (14)
Lamotrigine 4112 (12)
Topiramate 3937 (11)
AED, antiepileptic drug; SD, standard deviation.
a Geographic information is not available for Medicaid patients.
b The six most frequently prescribed AEDs amount to N100% because of polytherapy.
34 O. Devinsky et al. / Epilepsy & Behavior 56 (2016) 32–372.4.2. Predicting the model-predicted AED regimen
For each patient, the model-predicted AED regimen is the AED regi-
men having the highest success probability. This is determined for each
patient by “plugging in” every possible AED regimen into the model,
receiving the probability of success for that patient per regimen, and
choosing the regimen with the highest success probability. The set of
possible AEDs per patient is chosen as follows: denote by Tpre the
patient's AED regimen right before the index date. The set of possible
AEDs is the set of all index date treatment regimens, B, where Tpre→ B
occurred at least 50 times in the training population. The model-
predicted regimen may or may not be the AED regimen actually pre-
scribed at the index date. Kaplan–Meier analysis was used to determine
whether signiﬁcant differences in outcomes exist between cases
in which the model-predicted regimen was prescribed at the index
date and cases in which a different treatment was given (i.e., other
AED regimen).
2.4.3. Analysis of health-care service utilization
The analysis of health-care service utilization was performed in the
year after the index date using the test data set. In this analysis, we in-
vestigated several types of resource utilization, such as hospitalization
days and number of physician visits. For each utilization type, its actual
use (Uactual) was estimated directly from the data set (e.g., calculating
the average number of hospitalization days per patient in the year
after the index date). The expected use if model-predicted AED regimen
was always prescribedwas computed in the followingmanner. First, the
population of patients in the test data set was divided into those with
successful outcomes and those that failed and calculated the average
use per subpopulation: Usuccess and Ufail. Second, for each patient in
the test data set, the expected utilization was estimated for the
model-predicted AED regimen as p ∗ Usuccess + (1 − p) ∗ Ufail, where
p is the success probability for the patient and the model-predicted
AED. Finally, the average expected utilization over all persons in the
test data (Umodel) was computed, and used the difference between
Uactual and Umodel as an approximation for the expected decrease in
that utilization. The results presented for utilizations showed signiﬁcant
association with the outcome (t-test; false discovery rate [16], 0.05).
3. Results
Data from approximately 140,000 individuals matched inclusion
criteria regarding epilepsy diagnosis, age, pharmacy stability, and pa-
tient eligibility, and had a valid index date. Random samples of 40,000
patients for training and 10,000 patients for testing were selected.
With the additional constraint that an AED regimen must occur ≥50
times in the training set, the number of patients was reduced to
34,990 in the training set and 8715 in the test set. After requiring that
Tpre→ B occurs at least 50 times in the test population, the number of
patients in the test set for whom the model can make predictions was
reduced to 8292. There were a total of 52 different index date AED
regimens (monotherapies or combinations of AEDs) in the training set
satisfying this requirement. Demographics for the training set are
shown in Table 1. Results were stable across training and test sets.
The predictive model used selected features based on their associa-
tionwith the outcome, excluding those that were also highly correlated
to other features. The most dominating features were those related to
the complexity of the treatment and the history of treatment change
(e.g., number of AEDs at index date and pre-index date, number of treat-
ment changes at pre-index date, number of dose increases, number of
restarts). The next highly associated class of features was related to
the identity and mechanism(s) of action of the index date AED regimen
and pre-index date AEDs (e.g., old- or new-generation AEDs, treatments
containing clonazepam, GABA-augmenting mechanism). Demographic
features included age + age2, gender, and payer type. Background
conditions, as identiﬁed by diagnoses, procedures, or drugs, were also
included—mainly evidence of migraines, psychiatric disorders, andmetabolic/cardiovascular disorders. Finally, the prescribing physician
specialty also was used as input to the model. Fig. 1 depicts features
with the highest correlation to the outcome (i.e., correlation to a change
from the index drug regimen).
Our model exhibited greater predictive power than the baseline lo-
gistic regressionmodel (Fig. 2A), as demonstrated by the area under the
ROC curves (AUC = 0.715 vs AUC = 0.598, respectively). A retrospec-
tive analysis of the test set in the model showed that patients who
were given the model-predicted AED regimen (AED regimen with the
lowest likelihood of treatment change) had longer median survival
rates on average (i.e., longer time until a treatment change event) com-
paredwith patients receiving another AED regimen (median N 360 days
vsmedian of 239 days, 95% conﬁdence interval 229–252 days, p b 0.001;
Fig. 2B).
We examined whether physician-chosen AED regimens matched
with the model-predicted AED regimens (Fig. 3). The actual prescribed
AED regimen at the index date matched the model-predicted AED
regimen with the highest likelihood of treatment success in only 13%
of cases; there were large discrepancies in the frequency of use of cer-
tain AEDs/combinations between model-predicted AED regimens and
those actually prescribed.
There were several major resource savings based on the expected
use of the model-predicted AED regimens versus that observed in the
test population (Table 2). For all considered utilization types, patients
with successful outcomes had lower values on average than patients
with seizures that had unsuccessful outcomes with treatment. For
example, among the 8292 patients in the analysis, it was expected
that there would be 281.5 fewer epilepsy-related hospitalization days
on average if the model-recommended AED regimens were given
-0.15 -0.1 -0.05 0 0.05 0.1 0.15 0.2 0.25 0.3
MPR of clonazepam 12 months prior to ID
No. of newer-generation AEDs 12 months prior to ID
No. of discontinued treatment events 12 months prior to ID
No. of first-generation AEDs 12 months prior to ID
No. of restarts 6 months prior to ID
No. of absense-activity AEDs 12 months prior to ID
Age + Age2
No. of GABA-augmenting AEDs 12 months prior to ID
ID treatment has GABA-augmenting MOA
ID treatment contains clonazepam
No. of AED dose increases 12 months prior to ID
ID treatment contains a first-generation AED
No. of treatment change events 12 months prior to ID
No. of unique treatments 6 months prior to ID
No. of concomitant AEDs in ID treatment
Correlation to treatment failure
Fig. 1. Features of clinical interest with the strongest correlation to subsequent treatment change. AED, antiepileptic drug; ID, index date; MOA, mechanism of action; MPR, mean
possession ratio.
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days (particularly epilepsy-related), there were also fewer predicted
physician visits and a lesser need for medical procedures (particularly
epilepsy-related).
4. Discussion
We describe the pilot study for a predictive model that can identify
AED regimens with the lowest likelihood of subsequent treatment
change for an individual patient. The 72% area under ROC curve indi-
cates that this approach has predictive power and the time to treatment
change and utilization analyses verify its potential beneﬁt. The model
features were based on characteristics of the AEDs (e.g., mechanism
of action), the regimen (e.g., number of concomitant AEDs), and patient
features (e.g., age). Thismodel supports that older/ﬁrst-generation AEDs
are associatedwith poorer outcomes [17,18]. For example, another anal-
ysis of patients with epilepsy in the SDI database found that patients
taking ﬁrst-generation AEDs experienced epilepsy-related hospitaliza-
tions more frequently than those taking newer second-generation
AEDs and that prescriptions for second-generation AEDs were more1.0
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drug; AUC, area under the curve.common among neurologists and among physicians practicing near an
epilepsy center [18]. The association between second-generation AEDs
and better outcomes may reﬂect the beneﬁts of these AEDs and/or
care by more experienced clinicians. Treatment success increased with
age in our model, corroborating others' ﬁndings [19–22], likely
reﬂecting that causes of later-onset epilepsies (e.g., stroke) are more
often treatment-responsive or more likely to spontaneously resolve.
The model-predicted AED regimens produced signiﬁcantly better
than expected outcomes for patients—longer time to subsequent treat-
ment modiﬁcation event and reductions in predicted health-care
resource utilization (hospitalizations, AED use, specialist/physician
visits, and other procedures). A recent cost analysis compared patients
with epilepsy with stable AED regimens with those with unstable epi-
lepsy (AED added to the regimen) and found that patients with uncon-
trolled epilepsy usedmore services and incurred higher costs compared
with those with stable epilepsy (mean ± standard deviation, stable
$13,839 ± $31,355 vs unstable $23,238 ± $42,894) [23]. Our model's
recommendation system could reduce treatment changes and save
substantial costs while providing more stability and better outcomes
to patients.B
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Levetiracetam + gabapentin
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Fig. 3. Treatment distribution of actually given treatment versusmodel-predicted AED regimen. Of the 52 AED regimens in the training data set that were possibly predicted by themodel,
only treatment regimens used by at least 1% of patients are shown. AED, antiepileptic drug.
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of patients treated by multiple physician types as well geographic and
payer diversities [24]. The population demographics differ from that
normally seen in epilepsy clinics in that the population is older, poten-
tially over-representing symptomatic epilepsy and under-representing
younger cryptogenic cases, which may bias the algorithm's prediction
of AEDs. The limitations are partly offset by the power of the large
patient population and may also be compensated for because the
model includes patient and AED features when making AED regimen
predictions. The major limitation is that we could not evaluate seizure
freedom, reductions in seizure frequency, or quality of life. However,Table 2
Predictions of expected yearly health-care utilization savings in the test sample (8292 patients
Feature Observed utilization
(Uactual)a
No. of prescriptions for AED/SSRI/SNRI (30 days) 0.036049
No. of other prescriptions (30 days)b 0.162621
No. of days of epilepsy-related hospitalization 0.001802
No. of days of hospitalizationb 0.008453
No. of physician visit/days
Neurologist/specialist 0.018857
PCP/other 0.127702
Emergency medicine 0.002736
No. of epilepsy-related procedures 0.000247
No. of other proceduresb 0.060700
AED, antiepileptic drug; PCP, primary care physician; SSRI, selective serotonin reuptake inhibit
a In training data set.
b Not related to epilepsy.our assumption is that the treatment change outcome reﬂectsmany po-
tential adverse outcomes (e.g., poor efﬁcacy, poor tolerability, adverse
effect on a comorbid disorder, nonadherence, problems with drug
fulﬁllment); at the same time, treatment stability represents success
(however, it could also be a matter of patient or physician reluctance
to adjust treatment). The surrogate outcomes in claims data sets are
not ideal for these predictions; for instance, we know only that a pre-
scriptionwas given, reﬁlled orwithdrawn, butwe donot knowwhether
the medication was prescribed speciﬁcally for epilepsy or was taken as
recommended, nor do we know the reason for withdrawal. The high
rate of gabapentin (21%) and clonazepam (14%) use at the index date).
Expected utilization on
model-predicted AED (Umodel)
Delta (Uactual − Umodel) Yearly
delta
0.035308 0.000741 73.73
0.16142 0.001201 119.50
0.00171 0.000093 281.47
0.008271 0.000182 550.84
0.018599 0.000258 780.86
0.126633 0.001069 3235.41
0.002649 0.000088 266.34
0.000238 0.000009 27.24
0.060058 0.000642 1943.06
or; SNRI, serotonin–norepinephrine reuptake inhibitor.
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terns observed reﬂect the large proportion of the population treated
by nonspecialists, and in at least some of these patients, these AEDs
may have been prescribed because of comorbid pain, anxiety, or sleep
disorders as they were most often given in combination with other
AEDs. Indeed, certain comorbid conditions were features used by
the model to make its AED predictions. Future studies should evalu-
ate other populations/databases, other therapies (e.g., diet, surgery,
neurostimulation), as well as models with more speciﬁc outcomemea-
sures (e.g., seizure frequency) and perhaps even prospectively collected
electronic medical records.
5. Conclusions
This studywas a proof of concept, and a next step would be iterative
evaluations in other populations to reﬁne the algorithm. With the large
number of monotherapy and AED combination regimens that could be
prescribed, it is perhaps not surprising that only 13% of patients received
the model-predicted AED regimen, which suggests that many could
potentially beneﬁt if this model was available to clinicians as part of
a CDS. The algorithm designated one AED regimen as having the least
likelihood of subsequent treatment change (model-predicted AED
regimen), although several treatments may have had similar success.
Future studies may better deﬁne broader categories such as “ideal”
(i.e., the 13% in our study), “appropriate”, and “not recommended”.
Our model-predicted AED regimens suggest that a CDS system could
be developed to provide pertinent information and treatment recom-
mendations personalized for the individual patient proﬁle. This system
would augment the clinician's considerations (e.g., contraindications,
drug–drug interactions, comorbidities) to improve epilepsy care. No
single AED or AED combination will be optimal for all patients with
epilepsy. A CDS system could provide options likely to be effective and
eliminate diagnostics unlikely to impact care, improving individualized
treatment plans and outcomes in epilepsy.
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